A new landscape of host–protozoa interactions involving the extracellular vesicles world

Bruno Gavinho[1], Izadora Volpato Rossi[1], Ingrid Evans-Osses[1], Jameel Inal[2] and Marcel I. Ramirez[1,3]

[1]Departamento de Bioquímica e Biologia molecular, Universidade Federal de Paraná, Curitiba, Paraná, Brazil; [2]Bioscience Research Group, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK and [3]Instituto Oswaldo Cruz- Fiocruz, Rio de Janeiro, Brazil

Review Article

Abstract

Extracellular vesicles (EVs) are released by a wide number of cells including blood cells, immune system cells, tumour cells, adult and embryonic stem cells. EVs are a heterogeneous group of vesicles (∼30–1000 nm) including microvesicles and exosomes. The physiological release of EVs represents a normal state of the cell, raising a metabolic equilibrium between catabolic and anabolic processes. Moreover, when the cells are submitted to stress with different inducers or in pathological situations (malignancies, chronic diseases, infectious diseases.), they respond with an intense and dynamic release of EVs. The EVs released from stimulated cells *vs* those that are released constitutively may themselves differ, both physically and in their cargo. EVs contain protein, lipids, nucleic acids and biomolecules that can alter cell phenotypes or modulate neighbouring cells. In this review, we have summarized findings involving EVs in certain protozoan diseases. We have commented on strategies to study the communicative roles of EVs during host–pathogen interaction and hypothesized on the use of EVs for diagnostic, preventative and therapeutic purposes in infectious diseases. This kind of communication could modulate the innate immune system and reformulate concepts in parasitism. Moreover, the information provided within EVs could produce alternatives in translational medicine.

CAMBRIDGE
UNIVERSITY PRESS

Introduction

Neglected diseases, including leishmaniasis and Chagas disease, cause many thousands of deaths per annum, and are prevalent in several regions of the world, but mainly in underdeveloped regions, associated with poverty, in Asia, Africa and the Americas (Hotez *et al.*, 2017). The World Health Organization (WHO) have implemented various strategies to combat these diseases, including treatments, surveillance, improvement of housing and vector control. These have reduced significantly the prevalence and may result in the elimination of some diseases, such as human African trypanosomiasis, in the next years (WHO, 2016).

Chemotherapy against protozoan parasites is a field that needs to improve and different current challenges are being considered. Several drugs have been used for decades, but they have limited efficiency, because of the development of drug resistance, toxicity issues for patients and because their administration needs supervision thus incurring high costs for the health system (Klokousas *et al.*, 2003; Menegon *et al.*, 2016; Hart *et al.*, 2017). Hopefully, new antiprotozoal drugs will be made available in the next few years to follow the success of Artemisinin for malaria.

Efforts have been made in the post-genomic era to elucidate metabolic pathways in parasites with the aim of discovering specific targets that may be important for putative chemotherapies and also to improve current drugs used as treatments (Lechartier *et al.*, 2014; reviewed by Weigelt, 2010).

The challenge for improving therapies is a better understanding of host–pathogen interactions with an improved view on parasite adaptation and how the pathogen is able to manipulate its host environment. In recent decades, the research in this area has largely focused on the biomolecules secreted by parasites, many of which down-modulate host immune responses (reviewed in Evans-Osses *et al.*, 2015). Despite the progress in this field and the description of secreted products in different parasitic infections (Kaur *et al.*, 2001; Grébaut *et al.*, 2009; Coakley *et al.*, 2017), little is known about the mechanism(s) that regulate their interaction during host–pathogen interaction.

The current decade has seen immense activity in extracellular vesicle (EV) research, with some suggesting that EV release is the main process for modifying the phenotype of neighbouring cells. (Buck *et al.*, 2014; Kim *et al.*, 2016; Szempruch *et al.*, 2016). The physiological release of EVs represents a normal state of the cell. When the cells are submitted to stress with different inducers or in pathological situations (malignancies, chronic diseases, infectious diseases, etc), they respond with an intense and dynamic release of EVs (Cocucci and Meldolesi, 2015).

Table 1. Described action of parasite or host-derived Evs

Parasite	Exosome	Microvesicle	Parasite (P) or host (H)-derived?	Function	Ref.
Intracellular parasites					
Leishmania donovani	+		P	Export of proteins, delivery of parasite molecules into macrophages, modulate monocyte cytokine response	(11, 12)
Leishmania donovani and L. braziliensis	+		P	Enrichment of small RNAs with regulatory potential for host cells	(15)
Leishmania major	+		P	Modulate macrophages immune-related genes	(14)
Leishmania mexicana	+		P + H	Modulate macrophages immune-related genes	(13)
Trypanosoma cruzi	+	+	P	Secretion of parasite antigens	(18)
Trypanosoma cruzi		+	P + H	Increases parasite resistance to complement-mediated lysis and increases infectivity to host cells	(17, 20, 23)
Trypanosoma cruzi	+	+	P	Secretion of parasite proteins. Export of small RNAs. Modulate macrophage cytokine response. *In vivo*, induces a severe pathology and stimulates inflammation.	(18, 22, 24)
Plasmodium falciparum	+		P + H	Delivery of genes to another parasite	(28)
Plasmodium falciparum		+	P + H	Promotes differentiation of the sexual stage parasite and modulates the production of cytokines	(26)
Plasmodium falciparum		+	P + H	Microparticles levels in the blood correlate with the cases of malaria complicated by coma	(32)
Plasmodium falciparum, P. vivax, P. malariae		+	P + H	Infected patients have higher frequencies of plasma circulating EVs compared to healthy controls	(29)
Plasmodium yoelii	+		P + H	Carries parasite proteins (Application in immunization)	(26)
Plasmodium berghei	+	+	P + H	EVs from infected mice could induce cerebral malaria-like histopathological anomalies in healthy brain	(31)
Extracellular Parasites					
Toxoplasma gondii	+		H	Cell cycle regulation	(5,34,35)
Giardia intestinalis		+	P	Increase in parasite adhesion	(37)
Trypanosoma brucei	+		P	Immunomodulation, immunity evasion.	(4,39-41)
Trichomonas vaginalis	+		P	Immunomodulation, increase in parasite adhesion	(42, 43)

Although there is a plethora of literature describing the cargo or content of EVs, there are very few reports giving an exact description of the mechanism of their release or providing a clear understanding of the role of EVs in cell–cell communication.

The concept that EVs represent intercellular communicative vectors is based on the idea that the cells release a compartmentalized cargo with proteins, lipids, nucleic acids and biomolecules for uptake and integration into other cells. The intense flux of EVs between cells has been described intensively in recent years in many biological systems and we have summarized the findings in host–pathogen interactions in Table 1. With the increasing research in this field, more information has been obtained in characterization of EVs by the proteomic analysis of EVs and description of microRNAs contained in exosomes or microvesicles (MVs) from a variety of cell types (Alegre *et al.*, 2014; Eirin *et al.*, 2014; Zhang *et al.*, 2015). An integrated platform with the data obtained from proteomics results is available in Vesiclepedia (Kalra *et al.*, 2012).

During host–pathogen interaction, protozoan cells employ a vast set of evasion mechanisms to resist the attack of the immune system to penetrate into the organism and establish the infection. In recent years, EVs have been raised as a new element of pathogens' evasion mechanisms and modulate host–pathogen interaction (reviewed by Evans-Osses *et al.*, 2015; Coakley *et al.*, 2017). In this review, we summarize the role of EVs in host–pathogen interaction in diseases caused by protozoan parasites. However, our focus is to discuss the application of the knowledge learned in EVs in different models to develop alternatives to diagnostic, vaccine and translational medicine.

EVs have different modes of biogenesis

Exosomes and MVs are released from cells by energy-dependent processes and display differences in biogenesis, size, function and cargo. Exosomes (30–100 nm in diameter) are vesicles formed upon inward budding of endosomes resulting in intraluminal vesicles, within multivesicular bodies; exosomes are then released by exocytosis within the secretory pathway (reviewed by Evans-Osses *et al.*, 2015). Exosomes contain proteins derived from their cell of origin enriched for MHC class I and II, as well as heat-shock proteins and other proteins. MVs, however, are not derived from endocytosis, forming instead from a budding of the plasma membrane, occurring in response to activation of cellular processes (Silva *et al.*, 2017), in a Ca^{2+}-dependent manner and their size varies (100 nm– 1 μm). Briefly, external stimuli, such as interaction with

Fig. 1. Schematic representation of the dynamic flux of extracellular vesicles between host cells and parasites.

pathogen membranes, or some kind of cell damage result in Ca^{2+} influx to the cytoplasm or its release from internal sources. The rise in intracellular Ca^{2+} activates the calpain-mediated cleavage of the actin cytoskeleton. Flippase and floppase are then inhibited and scramblase is activated transporting the negatively charged phospholipids from the inner to the outer leaflet of the plasma membrane (Fujii *et al.*, 2015), resulting in MV formation with phosphatidylserine exposure. MV content is a reflection of the cellular state (Stratton *et al.*, 2015) and of the topographic region of the plasma membrane where it was formed (Fig. 1). Isolation of EVs involved in host–pathogen interaction can be performed from several sources, such as cell-protozoan *in vivo* or *in vitro* interaction/infection and also from parasite axenic culture. In addition to the *in vitro* approaches, vesicles can be obtained from patients and from laboratory animals' biofluids. Researchers use several techniques for the isolation of EVs, the most common and best accepted are differential centrifugation and size exclusion chromatography (Ramirez *et al.*, 2017). Detection of EVs is based on their biophysical properties and marker identification. The most used procedures for detection are Western blotting, nanoscale tracking analysis and electron microscopy (Gardiner *et al.*, 2013). In addition, protein quantification assays can be used to estimate the protein concentration of EVs.

During the long evolution of protozoan species, many pathogens have evolved to invade a wide range of hosts. Some of these needed to infect host cells to complete the life cycle and produce an infection. Pathogens need to interact with the immune system using an array of mechanisms to avoid host immune recognition and effector systems. The production of EVs is one of these strategies. Protozoan EVs could be involved in invasiveness, innate recognition, such as the complement system, immunomodulation and other processes, and this vesicle flux is essential to understand its pathogenicity. While there is much to be learned about host–pathogen interactions, exosomes and MVs are involved in the persistence of parasite populations within the host.

Intracellular parasites

Leishmania sp.

Leishmania parasites, the causative agents of leishmaniasis, are spread by the bite of phlebotomine sand flies and the disease manifests itself differently in people. The first suggestion of the release of exosome-like vesicles by *Leishmania* was a description of a large number of known eukaryotic exosomal proteins in *Leishmania* conditioned medium, suggesting a vesicle-based secretion system (Silverman *et al.*, 2008). Later, other authors confirmed these findings (Silverman *et al.*, 2010) showing that the release of leishmanial exosomes is upregulated by infection-like stressors (37 °C; ± pH 5.5), also altering the quantity of vesicles and their protein composition. In the same work, the uptake of GFP + exosomes by infected and non-infected macrophages was observed and *Leishmania* exosomal proteins HSP70 and HSP90 were detected in the cytosol of infected macrophages with specific antibodies. The selective induction of IL-8 secretion in a dose-dependent manner in macrophages treated with exosomes points to an exosomal delivery of molecular messages to infected as well as neighbouring uninfected macrophages. It has also been shown that the protein content of purified exosomes released by macrophages infected with *Leishmania mexicana* promastigotes displays a unique composition and abundance of functional groups of proteins, such as plasma membrane-associated proteins, chaperones and metabolic enzymes compared with the exosomal content of macrophages exposed to LPS and exosomal-free medium (Hassani and Olivier, 2013). Macrophages exposed to *Leishmania* release exosomes containing parasite surface protease GP63 that can modulate macrophage protein tyrosine phosphatases and transcription factors in a GP63-dependent manner, playing a notable role in dampening the innate inflammatory response (Hassani *et al.*, 2014). With a different focus, total *Leishmania* RNA was compared with exosomal RNA (Lambertz *et al.*, 2015) and it was shown that exosomes are selective and specifically enriched in small RNAs derived almost exclusively from non-coding RNAs, which could have regulatory

functions in cells, influencing host–pathogen interactions. The expression and function of an *L. major* phosphatase, LmPRL-1, that participates in the survival of the parasites inside macrophages were characterized recently (Leitherer *et al.*, 2017) and it has been shown that this protein is secreted mostly inside exosomes.

Trypanosoma cruzi

Recognized by WHO as one of the world's 13 most neglected tropical diseases, Chagas Disease is caused by the protozoan *Trypanosoma cruzi* and represents a relevant social and economic problem mainly in Latin American countries. *Trypanosoma cruzi* is able to invade most eukaryotic cells and has a complex life cycle involving mammalian hosts and insect vectors (WHO, 2002). The release of EVs has been described in epimastigote, metacyclic and tissue-derived trypomastigote stages of *T. cruzi*. These EVs may be released spontaneously or upon activation and they are able to interact with host cells (Silveira *et al.*, 1979; Gonçalves et al., 1991; Cestari *et al.*, 2012; Bayer-Santos *et al.*, 2013; Neves *et al.*, 2014). Ramirez *et al.* (2017) showed that vesicles obtained by the interaction of parasites with THP-1 monocytes cells contain components of mutual origin. Analysis of purified vesicles isolated from the supernatant of infected VERO (African Green Monkey kidney fibroblast-like) cells indicated that only ~10% of the total proteins detected were of *T. cruzi* origin. Also, it was described that cells infected with metacyclic trypomastigotes shed vesicles containing GP82, transialidases, GP63 and other parasite proteins (Bayer-santos *et al.*, 2013; Bautista-López *et al.*, 2017). Vesicles isolated from trypomastigote cultures induce different levels of proinflammatory cytokines and nitric oxide by macrophages in a heterogeneous manner (Nogueira *et al.*, 2015). MVs can also act as an immune evasion mechanism and result in increased parasite survival. For example, vesicles were shown to form a complex with C3 convertase, the central enzyme of the complement system, leading to the decay of the enzyme on the parasite surface. To escape the immune system, *T. cruzi* could use MVs containing TGF-β, promoting an increase in the number of intracellular parasites per cell (Cestari *et al.*, 2012; Ramirez *et al.*, 2017). Interestingly, the phenomenon of increased infectivity and inhibition of the complement system appears to be class specific, since vesicles derived from parasites of one class did not alter complement resistance and the invasion process of parasites from the other class (Wyllie and Ramirez, 2017). *In vivo*, it has been shown that mice previously inoculated with EVs derived from host–pathogen cell interaction from some metacyclic forms, upon receiving a challenge with metacyclic trypomastigotes forms from the same strain of *T cruzi*, resulted in increase of the parasitemia (Cestari *et al.*, 2012; Ramirez *et al.*, 2017). However, when mice were inoculated with a vesicle fraction prior to *T. cruzi* infection with tissue culture-derived trypomastigotes, this led to increased death and development of a more severe pathology compared with controls (Trocoli Torrecilhas *et al.*, 2009). This consolidates the concept that vesicles induced by parasites contribute to a pro-parasitic effect.

Plasmodium sp.

Malaria is a disease transmitted by *Anopheles* mosquitoes caused by protozoan parasites of the genus *Plasmodium* that infect erythrocyte and hepatocyte cells and was responsible for 212 million new infections and 4 29 000 deaths worldwide only in 2015. Although malaria can be a deadly disease, illness and death from malaria can usually be prevented (CDC, 2015). *Plasmodium falciparum* parasites directly communicate with other parasites and host cells using exosome-like vesicles that carry parasite proteins and antigens (Martin-Jaular *et al.*, 2011). These are able to deliver genes, as verified by their capacity to transfer drug resistance to parasites (Regev-Rudzki *et al.*, 2013). EVs promote differentiation of gametocytes, the sexual parasite stage for disease transmission to mosquito vector (Mantel *et al.*, 2013; Regev-Rudzki *et al.*, 2013).

EVs in *Plasmodium* infection can activate host immune cells and induce macrophage to produce proinflammatory cytokines IL-6, IL-12,IL-1 β and the anti-inflammatory cytokine IL-10 in a dose-dependent manner (Mantel *et al.*, 2013). Red blood cells parasitized with *Plasmodium* produce 10 times greater numbers of EVs than unparasitized cells (Nantakomol *et al.*, 2011) and infected patients have higher frequencies of plasma circulating vesicles compared with healthy controls (Campos *et al.*, 2010). The pathogenic role of EVs was studied *in vivo* in mice during *Plasmodium* infection, where the peak of plasma EVs coincided with the appearance of neurological manifestations of cerebral malaria (CM). In this model, fluorescently labelled EVs from mice with CM were transferred into infected mice and were shown to be attached to the endothelium of brain vessels. EVs transferred from activated endothelial cells into healthy recipient mice could induce CM-like histopathological anomalies in the brain (El-Assaad *et al.*, 2014). The relation between EV levels and pathology was demonstrated in patients by Nantakomol *et al.* (2011), whose group showed that plasma red blood cell-derived 'micro particle' concentrations were increased in patients with falciparum malaria in proportion to disease severity. Another study found increased numbers of circulating endothelial-derived vesicles in children with coma and severe malaria. In this work, it was also noticeable that during convalescence of the infection the number of endothelial-derived vesicles was significantly less than in the acute stage among patients with CM or coma and severe anaemia (Combes *et al.*, 2004).

Toxoplasma gondii

Toxoplasmosis is caused by *Toxoplasma gondii*, an intracellular protozoan that infects most nucleated cells found worldwide. *Toxoplasma gondii* infection may be asymptomatic in immunocompetent individuals but may cause severe, life-threatening illness in immunocompromised individuals and fetal complications if the mother experiences primary infection during pregnancy (Beauvillain *et al.*, 2009). Knowledge about exosomes secreted by *T. gondii*, or by cells infected by the protozoan is still very limited (Dlugonska and Gatkowska, 2016; Wowk *et al.*, 2017). Pope and Lässer (2013) hypothesize that exosome-like particles derived from *T. gondii*-infected fibroblasts could participate in the pathogenesis of the parasite and could be responsible for increasing mRNA levels associated with the neurological activity (Rab-13, thymosin) and their transfer to uninfected cells. The first proteomic profile from EVs of *T. gondii*, obtained from infected human foreskin fibroblast, reveals biomolecules already described in other models, such as CD63, HSP70 and calcium-binding proteins (Wowk *et al.*, 2017). Kim *et al.* (2016) observed changes in the proliferation of myoblasts treated with exosomes derived from infected cells (increase in the S phase).

Extracellular parasites

Giardia intestinalis

Giardia intestinalis is one of the most prevalent gastrointestinal pathogens on the planet that produce a diarrhoea with low inflammation and in some cases a chronic infection. The replicative form trophozoites need to adhere to the small intestine mucosa for survival. Secretory products involved in the communication between leucocytes and parasites was reported by Lee *et al.* (2012): trophozoites of *G. intestinalis* stimulated the

production of IL-8 which was responsible for the recruitment of neutrophils. As reviewed by Evans-Osses et al. (2015), it is suggested that the EVs represent an important form of communication and immunomodulation. Evans-Osses et al. (2017) identified the release of MVs from *G. intestinalis*, for the first time. The release of MVs may vary at different pH conditions (7.0 being the best condition) and time, and their release increases the adhesion capacity of the protozoa in Caco-2 (Caucasian colon adenocarcinoma cells) and their uptake and maturation by human dendritic cells (DCs). The pathogenesis of *Giardia* is not yet fully understood. Kho et al. (2013) demonstrated that HCT-8 (ileocaecal colorectal adenocarcinoma cells) infection with the protozoa could induce apoptosis, with signs of chromatin condensation and activation of caspase-3. It was demonstrated that extracts of parasites in contact with Caco-2 induced apoptosis, showing that the presence of the parasite is not necessary to start the process and suggesting that it could be dependent on EVs.

Trypanosoma brucei

Nten et al. (2010) identified for the first time that secretomes of *T. brucei* (*T. brucei brucei*, *T. brucei gambiense*) are associated with the pathway of exosomal biogenesis, being composed of proteins associated with pathological processes and the evasion of the immune system (metalopeptidases, GP63 protease). Eliaz et al. (2017) demonstrated that exosome secretion was abolished in *T. brucei* when transcription is inhibited (*Vps 36*), but production of exosomes continued in nanotubes. In addition, EVs could interfere in the social motility of parasites, repelling individuals from unfavorable conditions. Using time-lapse microscopy, it was demonstrated that exosomes were secreted for the transmission of stress signals. Szempruch et al. (2016) concluded that exosomes contain mostly flagellar and membrane proteins, such as surface glycoproteins and HSP70. These particles merge with erythrocytes, causing a decrease in circulation and possibly resulting in host anaemia. Furthermore, *T. brucei rhodesiense* can transfer vesicles containing serum resistance-associated proteins to non-human trypanosomes, allowing immune system evasion. A number of proteins contained in exosomes of *T. brucei gambiense* (HSP70, RAB protein, α and β tubulins, heavy chains of clathrin, histamine) have been identified (Geiger et al., 2010), with physiological functions not only for survival in the host but also for immunomodulation and intercellular communication. Enzymes involved in nucleotide metabolism were also identified, which could influence the inflammatory process.

Trichomonas vaginalis

Trichomonas vaginalis colonizes the human urogenital tract producing sexually transmitted disease known as trichomoniasis. Twu et al. (2013) identified for the first time the participation of *T. vaginalis* exosomes in immunomodulation and host–pathogen communication, allowing an improvement of adhesion when exosomes from highly adhesive parasites were incubated with a less adhesive parasite. Olmos-Ortiz et al. (2017) observed the immunomodulatory effects of *T. vaginalis* exosomes on murine macrophages. These vesicles induced an increase of IL-10, Il-6, TNF-α expression and nitric oxide production (cytotoxic and immunomodulatory activity). In addition, infected mice treated with exosomes increased IL-10 production and decreased IL-17 levels, resulting in the diminution of the inflammatory process without a reduction in parasitic load.

What is the next step: translational applications

The apparent role of EVs in a large number of biological processes, along with many of their intriguing features, forms the basis of extending EV analysis beyond basic research and into the clinical and therapeutic context (Revenfeld et al., 2014). EV isolation methods should be more specific, to ensure safe therapeutic possibilities (Alvarez-Erviti et al., 2011; Zhou et al., 2013; Momem-Heravi et al., 2014). In this regard, the development of portable point-of-care diagnostic tools for detecting circulating exosomes as biomarkers should be important in the future. Although much effort has been employed to understand the biology of EVs, we still need more experimental advancements to develop applied methods for the community. The need for such diagnostic tools in developing countries is very important as many are burdened by parasitic diseases and lack professional and material resources.

While naturally secreted exosomes may mediate beneficial effects in certain disease conditions, targeted exosomes loaded with therapeutic molecules may optimize efficacy while also reducing off-target delivery (Barile and Vassali, 2017; Moore et al., 2017). The lipid composition of their membranes may also increase antigenic stimulation (Zitvogel et al., 1998; Escudier et al., 2005). It is now imperative that the findings from the basic research are translated into biotechnological applications with greater urgency (Fontana et al., 2012).

Vaccines

Among numerous biomedical applications, the use of EVs in immunization may be explored in the future. The manner that EVs interact in antigen presentation allows the possibility of its use in developing a T cell-dependent response. In the past decade, it is laudable that philanthropic initiatives had been involved in the production of vaccines since diseases caused by unicellular eukaryotes are a major burden to tropical developing countries.

The genome of many protozoa has already been studied, and others have been initiated for the study of transcriptomes (Birkeland et al., 2010; Rastrojo et al., 2013; Morse et al., 2016). However, for ethical reasons, it is not possible to use live cell lines in an immunization protocol in humans (Beauvillain et al., 2009), especially considering the contraindication of live attenuated vaccines for immunocompromised patients.

Exosomes could, therefore, provide a new method for communication and for the exchange of antigenic information between cells in the immune system (Aline et al., 2004). Since they are of the same size as viruses, a similar uptake by antigen-presenting cells may be observed. Interestingly, the use of exosomes as a versatile tool for signal delivery compared with soluble molecules is gaining support due to their double-layered membrane (Trelis et al., 2016). In eukaryotic pathogens, both immuno-stimulatory and immuno-inhibitory functions have been reported for exosomes (Atayde et al., 2016). The ability of exosomes, especially those derived from DCs, to induce protective immune responses offers an alternative to DC-based vaccine (Beauvillain et al., 2007). DCs, presenters of antigens that participate in the onset of the adaptive response, are able to secrete EVs carrying MHC class II antigens, allowing the development of a specific T cell response; these EVs would be antigen-presenting vesicles (Zitvogel et al., 1998; Escudier et al., 2005). Intracellular parasites, bacteria and viruses that enter cells *via* an endocytic pathway are prime candidates for DC-based exosome immunogens. Vaccines consisting of exosomes will both preserve the positive aspects of live parasite vaccines and avoid their inherent risks (del Cacho et al., 2012).

Aline et al. (2004) demonstrated for the first time the participation of exosomes in protection against pathogens. They developed a vaccine composed of exosomes of DCs stimulated by *T. gondii*, capable of eliciting a TH1-mediated response. This protective capacity may be associated with DCs or exosome

Fig. 2. Different strategies to use EVs as vaccines and trigger antibodies production.


Fig. 3. Experimental steps for the Study of EVs and the possibilities of translation into clinics.

trafficking. DCs stimulated *in vitro* with *T. gondii* antigens secreted exosomes capable of inducing a significant humoral response in syngeneic and allogeneic mice, with a greater participation of IgA and reduction of cysts in the brain. Due to the low safety of administering an attenuated *T. gondii* vaccine to humans (Beauvillain *et al.*, 2007), the use of antigen-presenting vesicles is a possible way of stimulating T cells.

Exogenous derivatives of DCs stimulated with *Leishmania major* antigens, created a protective response with TH1 activation against cutaneous leishmaniasis (Schnitzer *et al.*, 2010).

Martin-Jaular *et al.* (2011) verified increased IgG in mice by treating them with exosomes of reticulocytes infected with *Plasmodium yoelli*. Antibodies were able to recognize erythrocytes infected with the protozoan. Some of the possible strategies are illustrated schematically in Figs 2 and 3.

However, although the use of exosomes allows for a cell-based vaccine, there are both conceptual and practical issues that need to be addressed before this potential application can become a reality. These include obtaining exosomes with the correct mix of antigens that provide protection, with the risks of introducing 'non-self' human molecules into a vaccinated individual (Schorey

et al., 2015). Through EVs, protozoa are able to initiate proinflammatory responses from target cells, such as increased production of interleukins. Therefore, it is suggested that the vesicles may have the added benefit of acting as adjuvants. Exosomes have also been shown to induce anti-tumour immunity in the absence of adjuvants or heat treatment (Greening *et al.*, 2015; Morishita *et al.*, 2016) thus suggesting the use of exosomes as adjuvant because of the ability of these structures to act as molecule carriers. Due to their physical properties, EVs could enhance the immunogenicity of antigens. A satisfactory response must activate specific arms of the immune system, such as the cell-mediated response, and possibly constitute an effective immunomodulatory effect for diseases that lack an effective immunogen.

Diagnostic

The level of EVs in human serum could be a marker of disease status (Pisitkun *et al.*, 2004; Wekesa *et al.*, 2014; Kim *et al.*, 2017). As EVs reflect the proteomic content of the cells from which they are derived, it is possible to use them for disease detection, as first investigated in tumours (Santiago-Dieppa *et al.*,

2014). EV cargo can also be involved in disease prognosis. The nature of the vesicles allows a means of transport, free of blood degradation. This has proven to be particularly significant for the use of miRNA as valuable biomarkers because most RNA in blood exists within EVs (Revenfeld *et al.*, 2014). Recently, Melo *et al.* (2015) detected cancer-cell derived exosomes containing a high concentration of cell surface proteoglycan, glypican-1. It was showed that glypican-1 is a pan-specific marker of cancer exosomes, specifically detected in the serum of individuals with pancreatic cancer. Many parasitic diseases have host–pathogen interactions with poorly studied pathogenesis. As EVs participate in these processes, the clinical investigation should consider the detection of EVs derived from parasites or hosts in biological fluids. When the *T. cruzi* secretome was analysed after 16 h of ultracentrifugation, proteins involved in the pathogenicity of the protozoa, such as GP63 and Aminopeptidase P, were found to be increased within the EVs compared with the supernatant fraction (Bayer-Santos *et al.*, 2014). According to Geiger *et al.* (2010) metallopeptidase thimet oligopeptidase A (M3 family) is the first of the group to be identified in protozoa, resulting in a potential marker for diagnosis in *T. brucei*. The presence of proteins on the EV lipid bilayer such as the tetraspanins could present targets for detection by monoclonal antibodies.

It is also possible that nucleic acid, present in EVs has some diagnostic potential (Eirin *et al.*, 2014; Melo *et al.*, 2015; Zhang *et al.*, 2015). Such a molecular diagnosis of parasitic diseases could offer high sensitivity and specificity, compared with microscopic examination, reducing shortcomings and it can be standardized (Stensvold *et al.*, 2011). As microscopy remains labour intensive and highly observer-dependent, molecular detection techniques, such as real-time polymerase chain reaction (PCR), are excellent alternatives, in particular in settings where the number and range of parasitic infections are low and personnel costs are substantial (Lieshout and Roestenberg, 2015). Serological assays also have limitations. For example, conventional serological assays for *T. cruzi* may lead to unspecific reactions (false positives) due to cross-reactivity with antibodies elicited by other pathogens, e.g., *Leishmania* spp. and *Trypanosoma rangeli*. Because of a lack of a single test with high sensitivity/specificity, the WHO recommends positive results from two different serological tests for a confirmation of *T. cruzi* infection (Zingales, 2017). In that context, diagnostic techniques based on molecular targets are becoming more popular.

Accordingly, as reviewed by Inamdar *et al.* (2017), expression profiling can be useful as a diagnostic tool in diseases that lack definitive biomolecular biomarkers. The detection of nucleic acids in EVs obtained from clinical samples, like feces, could become a regular procedure. It was shown by Liu *et al.* (2016) that it is possible to obtain a suitable Fecal Suspension Particle-Size Distribution by NanoSight™ and E.M Feces from mice with a combination of dilution of feces in PBS, spun down at 10 000 × **g** for 5 min by centrifugation and then filtered to remove the debris. Moreover, EVs were isolated from feces homogenized in PBS, using exoEasy Maxi Kit™ spin columns (Qiagen©), followed by RNA isolation using miRCURY™ RNA Isolation Kit (Exiqon©) with on-column DNase treatment (Qiagen©).

Other types of analytes that could be studied in the exosomal space, such as lipids, might represent good biomarkers to investigate in the near future. All these findings provide an important base to continue research in parasite-derived exosomes as diagnostic targets and demonstrating their utility as clinical biomarkers (Sánchez-Ovejero *et al.*, 2016).

Therapeutics

EVs participate in cellular traffic thereby influencing pathophysiological conditions and it is this capacity to be delivered that could

be extrapolated for therapeutic purposes as well (Moore *et al.*, 2017). Mammalian stem cells EVs have been shown to be involved in cell proliferation and improved the renal function of cisplatin-induced acute kidney injury in rats (Zhou *et al.*, 2013). For the same model, it was also demonstrated that exosomes could deliver miRNA for up-regulation of anti-apoptosis genes and reduce mortality caused by cisplatin (Bruno *et al.*, 2012). Intranasal delivered exosomes were taken up by microglial cells, which are key mediators in neuro-inflammatory diseases; delivery of curcumin-loaded exosomes resulted in a reduction in activated microglial cells in both encephalitis and LPS-induced brain inflammation models (as reviewed by Inamdar *et al.*, 2017).

There are different ways to explore the potential of therapeutic EVs. For example, macrophage-derived MVs may represent a way of converting an autologous intrinsically biocompatible sub-cellular entity into a drug delivery system able to carry both nanoparticles and drugs. In this regard, it would be of interest to demonstrate that cellular MVs might be loaded with different drug molecules while simultaneously enclosing nanoparticles that enable spatially controlled drug delivery.

Silva *et al.* (2015) encapsulated different drugs with magnetic nanoparticles within MVs. The magnetic properties of the nanoparticles could influence the uptake of the loaded MVs, and such a combination could represent a model for the delivery of different types of drugs, as for example in cancer-therapy. The possibility of producing MVs from different cell populations could improve such association, resulting in a specific delivery method. Strategies for loading molecular cargo in exosomes and related efficacies differ based on the chemistry of the loaded molecule (as reviewed by Inamdar *et al.*, 2017). In this regard, it is possible to explore the loading capacity of EVs for different antiprotozoal drugs.

Besides drug delivery, nucleic acids have also been involved in therapeutic purposes. The specificity imparted by targeted exosomes, the capacity to load exogenous genetic cargoes, the ability to systemically administer the gene therapy and immune evasion by exosomes are valuable properties for future oligonucleotide therapy applications (Alvarez-Erviti *et al.*, 2011). In addition, exosome-transferred miRNAs are emerging as novel regulators of cellular function (Alexander *et al.*, 2015). Momem-Heravi *et al.* (2014) loaded exosomes with microRNA (miR-155, with electroporation) or inhibitor to be uptaken by hepatocytes or macrophages, respectively. Exosome-mediated inhibition was superior to conventional transfection models. Alvarez-Erviti *et al.* (2011) through *in vivo* administration of exosome-loaded siRNA were able to specifically knockdown BACE 1 (protease involved in Alzheimer´s Disease).

Delivery of drugs or nucleic acids though EVs to treat parasitic diseases have not been explored yet. However, mammalian models are promising. We speculate that if EV-loaded microRNAs inhibit genes involved in the pathogenesis of protozoa, it will significantly affect parasite–host interactions. MicroRNA could specifically regulate protozoan virulence through inhibition of invasiveness-related genes, or improve the host immune system by up-regulating immune-related genes. Another promising strategy relies on gene-editing tools, like CRISPR/Cas 9. CRISPR/Cas 9 is a technology based on a known mechanism from bacteria and archaea that enable the organisms to respond to and eliminate invading genetic material. The CRISPR/Cas9 system consists of the Cas9 nuclease and a single guide RNA, which are used to guide effector endonucleases that target DNA sequence of interest based on sequence complementarity (Chira *et al.*, 2017). While *in vivo* delivery of this system has a low efficiency, the use of exosomes loaded with CRISPR/Cas9 showed a promising result in cancer. Kim *et al.* (2017) demonstrated a reduced apoptosis in ovarian cancer by suppressing poly (ADP-ribose) polymerase-1, with CRISPR/CAs9 loaded exosomes. While there is a long way

in medical approaches concerning the application of this tool, a CRISPR/Cas9 system editing pathogen genes will allow a better understanding of host–pathogen interaction. This knowledge could provide the possibility of designing novel targets for therapeutic interventions.

Concluding remarks

The strategies debated in this work are speculations of what is to come from the rapidly expanding field of EVs. It is clear that 'trial-and-error' research is necessary to expand applications in the routine medical laboratory. Since parasitic diseases are common in developing countries, translation into clinics must involve low-cost strategies. If the participation of EVs in cell communication models is becoming highly proven, it is only a matter of time until biotechnology is able to deliver accessible procedures.

Are EV detection methods going to emerge as markers for next-generation diagnostics of protozoa?

Are EVs a satisfactory alternative for the immunization of poorly responsive populations?

Can EVs be considered a delivery system for drugs to reduce off-target effects on parasitological diseases?

Is Clinical parasitology going to translate EV-based research in the future?

Can gene-editing systems interfere in host–pathogen communication, acting as a therapeutic alternative?

Conflicts of interest. None.

Ethical standards. Not applicable.

References

Alegre E, Sanmamed MF, Rodriguez C, Carranza O, Martín-Algarra S and González A (2014) Study of circulating MicroRNA-125b levels in serum exosomes in advanced melanoma. *Archives of Pathology & Laboratory Medicine* 138, 828–832.

Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T, Seabra MC, Round JL, Ward D and O´Connell RM (2015) Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. *Nature Communications* 6, 1–16.

Aline F, Bout D, Amigorena S, Roingeard P and Dimier-Poisson I (2004) *Toxoplasma gondii* Antigen-pulsed-dendritic cell derived exosomes induce a protective immune response against *T. gondii* infection. *Infection and Immunity* 72, 4127–4137.

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S and Wood MJA (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nature Biotechnology* 29, 341–345.

Atayde VD, Hassani K, Filho ASL, Borges AR, Adhikari A, Martel C and Olivier M (2016) *Leishmania* exosomes and other virulence factors: impact on innate immune response and macrophage functions. *Cellular Immunology* 309, 7–18.

Barile L and Vassali G (2017) Pharmacology & therapeutics exosomes : therapy delivery tools and biomarkers of diseases. *Pharmacology & Therapeutics* 174, 63–78.

Bautista-López NL, Ndao M and Camargo V (2017) Characterization and diagnostic application of *Trypanosoma cruzi* Trypomastigote excreted-secreted antigens shed in extracellular vesicles released from infected mammalian cells. *Journal of Clinical Microbiology* 55, 744–758.

Bayer-Santos E, Aguilar-Bonavides C, Rodrigues SP, Cordero EM, Marques AF, Varela-Ramirez A, Choi H, Yoshida N, da Silveira JF and Almeida IC (2013) Proteomic analysis of *Trypanosoma cruzi* secretome : characterization of two populations of extracellular vesicles and soluble proteins. *Journal of Proteome Research* 12, 883–897.

Bayer-Santos E, Lima FM, Ruiz JC, Almeida IC and Silveira JF (2014) Characterization of the small RNA content of *Trypanosoma cruzi* extracellular vesicles. *Molecular Biochemistry Parasitology* 193, 71–74.

Beauvillain C, Ruiz S, Guiton R, Bout D and Dimier-Poisson I (2007) A vaccine based on exosomes secreted by a dendritic cell line confers protection against *T. gondii* infection in syngeneic and allogeneic mice. *Microbes and Infection* 9, 1614–1622.

Beauvillain C, Juste MO, Dion S, Pierre J and Dimier-Poisson I (2009) Exosomes are an effective vaccine against congenital toxoplasmosis in mice. *Vaccine* 27, 1750–1757.

Birkeland SR, Preheim SP, Davids BJ, Cipriano MJ, Palm D, Reiner DS, Svärd SG, Gillin FD and McArthur AG (2010) Transcriptome analyses of the *Giardia lamblia* life cycle. *Molecular & Biochemical Parasitology* 174, 62–65.

Bruno S, Grange C, Collino F, Deregibus MC, Cantaluppi V, Biancone L, Tetta C and Camussi G (2012) Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. *PLoS ONE* 7, 1–11.

Buck AH, Coakley G, Simbari F, McSorley HJ, Quintana JF, Bihan TL, Kumar S, Abreu-Goodger C, Lear M, Harcus Y, Ceroni A, Babayan SA, Blaxter M, Ivens A and Maizels RM (2014) Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity. *Nature Communications* 5.

Campos FMF, Franklin BS, Teixeira-Carvalho A, Filho ALS, de Paula SCO, Fontes CJ, Brito CF and Carvalho LH (2010) Augmented plasma microparticles during acute *Plasmodium vivax* infection. *Malaria Journal* 9, 327–334.

CDC–Center for Disease Control and Prevention (2015). https://www.cdc.gov/malaria/about/index.html.

Cestari I, Ansa-Addo E, Deolindo P, Inal JM and Ramirez MI (2012) *Trypanosoma cruzi* immune evasion mediated by host cell-derived microvesicles. *The Journal of Immunology* 188, 1942–1952.

Chira S, Gulei D, Hajitou A, Zimta A, Cordelier P and Berindan-Neagoe I (2017) CRISPR/cas9: transcending the reality of genome editing. *Molecular Therapy. Nucleic Acids* 7, 211–222.

Coakley G, McCaskill JL, Borger JG, Simbari F, Robertson E, Millar M, Harcus Y, McSorley HJ, Maizels RM and Buck AH (2017) Extracellular vesicles from a helminth parasite suppress macrophage activation and constitute an effective vaccine for protective immunity. *Cell Reports* 19, 1545–1557.

Cocucci E and Meldolesi J (2015) Ectosomes and exosomes: shedding the confusion between extracellular vesicles. *Trends Cell Biology* 25, 364–372.

Combes V, Taylor TE, Juhan-Vague I, Mège JL, Mwenechanya J, Tembo M, Grau GE and Molyneux ME (2004) Circulating endothelial microparticles in Malawian children with severe falciparum malaria complicated with coma. *Journal of American Medical Association* 291, 2542–2544.

del Cacho E, Gallego M, Lee SH, Lillehoj HS, Quilez J, Lillehoj EP and Sánchez-Acedo C (2012) Induction of protective immunity against *Eimeria tenella*, *Eimeria maxima*, and *Eimeria acervulina* infections using dendritic cell-derived exosomes. *Infection and Immunity* 80, 1909–1916.

Dlugonska H and Gatkowska J (2016) Exosomes in the context of *Toxoplasma gondii*–host communication. *Annals of Parasitology* 62, 169–174.

Eirin A, Riester SM, Zhu XY, Tang H, Evans JM, O´Brien D, van Wijnen AJ and Lerman LO (2014) MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. *Gene* 551, 55–64.

El-Assaad F, Wheway J, Hunt NH, Grau GER and Combes V (2014) Production, fate and pathogenicity of plasma microparticles in murine cerebral malaria. *Plos Pathogens* 10.

Eliaz D, Kannan S, Shaked H, Arvatz G, Tkacz ID, Binder L, Ben-Asher HW, Okalang U, Chikne V, Cohen-Chalamish S and Michaeli S (2017) Exosome secretion affects social motility in *Trypanosoma brucei*. *PLoS Pathogens* 13. doi: 10.1371/journal.ppat.1006245

Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, Flament C, Leboulaire C, Borq C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E and Zitvogel L (2005) Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. *Journal of Translational Medicine* 3, 10.

Evans-Osses I, Reichembach LH and Ramirez MI (2015) Exosomes or microvesicles? Two kinds of extracellular vesicles with different routes to

modify protozoan-host cell interaction. *Parasitology Research* **114**, 3567–3575.

Evans-Osses I, Mojoli A, Monguió-Tortajada MM, Marcilla A, Aran V, Amorin M, Inal J, Borràs FE and Ramirez MI (2017) Microvesicles released from *Giardia intestinalis* disturbs host-pathogen response *in vitro*. *European Journal of Cell Biology* **96**, 131–142.

Fontana JM, Alexander E and Salvatore M (2012) Translational research in infectious diseases: current paradigms and challenges ahead. *Translational Research* **159**, 430–456.

Fujii T, Sakata A, Nishimura S, Eto K and Nagata S (2015) TMEM16F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets. *Proceedings of the National Academy of Sciences of the USA* **112**, 12800–5.

Gardiner C, Ferreira YJ, Dragovic RA, Redman CWG and Sargent IL (2013) Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. *Journal of Extracellular Vesicles* **2**, 19671.

Geiger A, Hirtz C, Bécue T, Bellard E, Centeno D, Gargani D, Rossignol M, Cuny G and Peltier J (2010) Exocytosis and protein secretion in *Trypanosoma*. *BMC Microbiology* **10**, 20.

Gonçalves MF, Umezawa ES, Katzin AM, de Souza W, Alves MJ, Zingales B and Colli W (1991) *Trypanosoma cruzi*: shedding of surface antigens as membrane vesicles. *Experimental Parasitology* **72**, 43–53.

Grébaut P, Chuchana P, Brizard JP, Demettre E, Seveno M, Bossard G, Jouin P, Vincendeau P, Bengaly Z, Boulangé A, Cuny G and Holzmuller P (2009) Identification of total and differentially expressed excreted-secreted proteins from *Trypanosoma congolense* strains exhibiting different virulence and pathogenicity. *International Journal for Parasitology* **39**, 1137–1150.

Greening DW, Gopal SK, Xu R, Simpson RJ and Chen W (2015) Exosomes and their roles in immune regulation and cancer. *Seminars in Cell & Development Biology* **40**, 72–81.

Hart CJS, Munro T, Andrews KT, Ryan JH, Riches AG and Skinner-Adams TS (2017) A novel in vitro image-based assay identifies new drug leads for giardiasis. *International Journal for Parasitology: Drugs and Drug Resistance* **7**, 83–89.

Hassani K and Olivier M (2013) Immunomodulatory impact of leishmania-induced macrophage exosomes: a comparative proteomic and functional analysis. *Plos Neglected Tropical Diseases* **7**. doi: 10.1371/journal.pntd.0002185

Hassani K, Shio MT, Martel C, Faubert D and Olivier M (2014) Absence of metalloprotease GP63 alters the protein content of leishmania exosomes. *Plos ONE* **9**. doi: 10.1371/journal.pone.0095007

Hotez PJ, Basañez M, Acosta-Serrano A and Grillet ME (2017) Venezuela and its rising vector-borne neglected diseases. *PLoS Neglected Tropical Diseases* **11**. doi: org/10.1371/journal.pntd.0005423

Inamdar S, Nitiyanandan R and Rege K (2017) Emerging applications of exosomes in cancer therapeutics and diagnostics. *Bioengineering & Translational Medicine* **2**, 70–80.

Kalra H, Simpson RJ, Ji H, Aikawa E, Atevogt P, Askenase P, Bond VC, Borràs FE, Breakefield X, Budnik V, Buzas E, Camussi G and Clayton A (2012) Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. *PLoS Biology* **10**, e1001450.

Kaur H, Ghosh S, Samra H, Vinayak VK and Ganguly NK (2001) Identification and characterization of an excretory-secretory product from *Giardia lamblia*. *Parasitology* **123**, 347–356.

Kho WH, Geurden T, Paget T, O´Handley R, Steuart RF, Thompson RC and Buret AG (2013) *Giardia duodenalis* assemblage-specific induction of apoptosis and tight junction disruption in human intestinal epithelial cells: effects of apoptosis and tight junction disruption in human intestinal epithelial cells: effects of mixed infections. *Journal of Parasitology* **99**, 353–358.

Kim MJ, Jung B, Cho J, Song H, Pyo K, Lee JM, Kim M and Chai J (2016) Exosomes secreted by *Toxoplasma gondii*-infected L6 cells: their effects on host cell proliferation and cell cycle changes. *Korean Journal of Parasitology* **54**, 147–154.

Kim SM, Yang Y, Ih SJ, Hong Y, Seo M and Jang M (2017) Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. *Journal of Controlled Release* **28**, 8–16.

Klokousas A, Shani S, Hladky SB, Barrand MA and Veen HW (2003) ABC transporters and drug resistance in parasitic protozoa. *International Journal of Antimicrobial Agents* **22**, 301–317.

Lambertz U, Oviedo Ovando ME, Vasconcelos EJ, Unrau PJ, Myler PJ and Reiner NE (2015) Small RNAs derived from tRNAs and rRNAs are highly enriched in exosomes from both old and new world Leishmania providing evidence for conserved exosomal RNA packaging. *BMC Genomics* **16**, 1–16.

Lechartier B, Rybniker J, Zumla A and Cole ST (2014) Tuberculosis drug discovery in the post-post-genomic era. *EMBO Molecular Medicine* **6**, 158–168.

Lee HY, Hyung S, Lee NY, Yog TS, Han SH and Park SJ (2012) Excretory-secretory products of *Giardia lamblia* induce interleukin-8 production in human colonic cells *via* activation of p38, ERK1/2, NK-κB and AP-1. *Parasite Immunology* **34**, 183–198.

Leitherer S, Clos J, Liebler-Tenorio EM, Schleicher U, Bogdan C and Soulat D (2017) Characterization of the protein tyrosine phosphatase LmPRL-1 secreted by Leishmania major *via* the exosome pathway. *Infection and Immunity* **85**, 1–19.

Lieshout VL and Roestenberg M (2015) Clinical consequences of new diagnostic tools for intestinal parasites. *Clinical Microbiology and Infection* **21**, 520–528.

Liu S, da Cunha AP, Rezende RM, Cialic R, Wei Z, Bry L, Comstock LE, Gandhi R and Weiner HL (2016) The host shapes the Gut Microbiota *via* fecal MicroRNA. *Cell Host & Microbe* **19**, 32–43.

Mantel P, Hoang AN, Goldowitz I, Potashnikova D, Hamza B, Vorobjev I, Ghiran I, Toner M, Irimia D, Ivanov AR, Barteneva N and Marti M (2013) Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system. *Cell Host and Microbe* **13**, 521–534.

Martin-Jaular L, Nakayasu ES, Ferrer M, Almeida IC and Portillo HA (2011) Exosomes from *Plasmodium yoelii*-infected reticulocytes protect mice from lethal infections. *PLoS ONE* **6**. doi: 10.1371/journal.pone.0026588.

Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D and Kalluri R (2015) Glypican1 identifies cancer exosomes and facilitates early detection of cancer. *Nature* **523**, 177–182.

Menegon M, Nurahmed AM, Talha AA, Nour BYM and Severini C (2016) Molecular surveillance of antimalarial drug resistance related genes in *Plasmodium falciparum* isolates from Eritrea. *Acta Tropica* **157**, 158–161.

Momem-Heravi F, Bala S, Bukong T and Szabo G (2014) Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. *Nanomedicine: Nanotechnology, Biology, and Medicine* **10**, 1517–1527.

Moore C, Kosgodage U, Lange S and Inal JM (2017) The emerging role of exosome and microvesicle–(EMV-) based cancer therapeutics and immunotherapy. *International Journal of Cancer* **141**, 428–436.

Morishita M, Takahashi Y, Matsumoto A, Nishikawa M and Takakura Y (2016) Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA. *Biomaterials* **111**, 55–65.

Morse D, Daoust P and Benribaque S (2016) A transcriptome-based perspective of cell cycle regulation in dinoflagellates. *Protist* **167**, 610–621.

Nantakomol D, Dondorp AM, Krudsood S, Udomsanqpetch R, Pattanapanyasat K, Combes V, Grau GE, White NJ, Viriyavejakul P, Day NP and Chotivanich K (2011) Circulating red cell–derived microparticles in human malaria. *The Journal of Infectious Diseases* **203**, 700–706.

Neves RFC, Fernandes ACS, Meyer-Fernandes JR and Souto-Padrón T (2014) *Trypanosoma cruzi* -secreted vesicles have acid and alkaline phosphatase activities capable of increasing parasite adhesion and infection. *Parasitology Research* **113**, 2961–2972.

Nogueira PM, Ribeiro K, Silveira AC, Campos JH, Martins-Filho OA, Bela SR, Campos MA, Pessoa NL, Colli W, Alves MJ, Soares RP and Torrecilhas AC (2015) Vesicles from different *Trypanosoma cruzi* strains trigger differential innate and chronic immune responses. *Journal of Extracellular Vesicles* **4**, 1–16.

Nten CMA, Sommerer N, Rofidal V, Hirtz C, Rossignol M, Cuny G, Peltier J and Geiger A (2010) Excreted/secreted proteins from *Trypanosome* procyclic strains. *Journal of Biomedicine and Biotechnology* **2010**. doi: 10.1155/2010/212817

Olmos-Ortiz LM, Barajas-Mendiola MA, Barrios-Rodiles M, Castellano LE, Arias-Negrete S, Avila EE and Cuéllar-Mata P (2017) *Trichomonas vaginalis* exosome-like vesicles modify the cytokine profile and reduce inflammation in parasite-infected mice. *Parasite Immunology* **39**. doi: 10.1111/pim.12426.

Pisitkun T, Shen R and Knepper MA (2004) Identification and proteomic profiling of exosomes in human urine. *Proceedings of the National Academy of Sciences* **101**, 13368–13373.

Pope SM and Lässer C (2013) *Toxoplasma gondii* infection of fibroblasts causes the production of exosome-like vesicles containing a unique array of mRNA and miRNA transcripts compared to serum starvation. *Journal of Extracellular vesicles* 2, 22484.

Ramirez MI, Deolindo P, de Messias-Reason IJ, Arigi EA, Choi H, Almeida IC and Evans-Osses I (2017) Dynamic flux of microvesicles modulate parasite–host cell interaction of *Trypanosoma cruzi* in eukaryotic cells. *Cellular Microbiology* 19, 1–15.

Rastrojo A, Carrasco-Ramiro F, Martín D, Crespillo A, Reguera RM, Aguado B and Requena JM (2013) The transcriptome of Leishmania major in the axenic promastigote stage: transcript annotation and relative expression levels by RNA-seq. *BMC Genomics* 14, 223.

Regev-Rudzki N, Wilson DW, Carvalho TG, Sisquella X, Coleman BM, Rug M, Bursac D, Angrisano F, Gee M, Hill AF, Bum J and Cowman AF (2013) Cell-Cell communication between malaria-infected red blood cells *via* exosome-like vesicles. *Cell* 153, 1120–1133.

Revenfeld AL, Baek R, Nielsen HM, Stenballe A, Varming K and Jorgensen M (2014) Diagnostic and prognostic potential of extracellular vesicles in peripheral blood. *Clinical Therapeutics* 36, 830–846.

Sánchez-Ovejero C, Benito-Lopez F, Díez P, Casulli A, Siles-Lucas M, Fuentes M and Manzano-Román R (2016) Sensing parasites: proteomic and advanced bio-detection alternatives. *Journal of Proteomics* 136, 145–156.

Santiago-Dieppa DR, Steinberg J, Gonda D, Cheung VJ, Carter BS and Chen CC (2014) Extracellular vesicles as a platform for "liquid biopsy" in glioblastoma patients. *Expert Review of Molecular Diagnostics* 14, 819–825.

Schnitzer JK, Berzel S, Fajardo-Moser M, Remer KA and Moll H (2010) Fragments of antigen-loaded dendritic cells (DC) and DC-derived exosomes induce protective immunity against *Leishmania major*. *Vaccine* 28, 5785–5793.

Schorey JS, Cheng Y, Singh PP and Smith VL (2015) Exosomes and other extracellular vesicles in host-pathogen interactions. *EMBO Reports* 16, 24–43.

Silva AK, Luciani N, Gazeau F, Aubertin K, Bonneau S, Chauvierre C, Letourneur D and Wilhelm C (2015) Combining magnetic nanoparticles with cell derived microvesicles for drug loading and targeting. *Nanomedicine: Nanotechnology, Biology, and Medicine* 11, 645–655.

Silva AM, Teixeira JH, Almeida MI, Gonçalves RM, Barbosa MA and Santos SG (2017) Extracellular vesicles: immunomodulatory messengers in the context of tissue repair/regeneration. *European Journal of Pharmaceutical Sciences* 98, 86–95.

Silveira JFDA, Abrahamsohn PA and Colli W (1979) Plasma membrane vesicles isolated from epimastigote forms of *Trypanosoma cruzi*. *Biochimica et Biophysica Acta* 550, 222–232.

Silverman JM, Chan SK, Robinson DP, Dwyer D, Nandan D, Foster LJ and Reiner NE (2008) Proteomic analysis of the secretome of *Leishmania donovani*. *Genome Biology* 9, 1–21.

Silverman JM, Clos J, de´Oliveira CC, Shirvani O, Fang Y, Wang C, Foster LJ and Reiner NE (2010) An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. *Journal of Cell Science* 123, 842–852.

Stensvold CR, Lebbad M and Verweij JJ (2011) The impact of genetic diversity in protozoa on molecular diagnostics. *Trends in Parasitology* 27, 53–58.

Stratton D, Moore C, Antwi-Baffour S, Lange S and Inal J (2015) Microvesicles released constitutively from prostate cancer cells differ biochemically and functionally to stimulated microvesicles released through sublytic C5b-9. *Biochemical and Biophysical Research Communications* 460, 589–595.

Szempruch AJ, Sykes SE, Kief R, Denison L, Becker AC, Gartrell A, Martin WJ, Nakayasu ES, Aldeida IC, Hajduk SL and Harrington JM (2016) Extracellular vesicles from *Trypanosoma brucei* mediate virulence factor transfer and cause host anemia. *Cell* 164, 246–257.

Trelis M, Galiano A, Bolado A, Toledo R, Marcilla A and Bernal D (2016) Subcutaneous injection of exosomes reduces symptom severity and mortality induced by *Echinostoma caproni* infection in BALB/c mice. *International Journal for Parasitology* 46, 799–808.

Trocoli Torrecilhas AC, Tonelli RR, Pavanelli WR, da Silva JS, Schumacher RI, de Souza W, E Silva NC, de Aldeida Abrahamsihn I, Colli W and Manso Alves MJ (2009) *Trypanosoma cruzi*: parasite shed vesicles increase heart parasitism and generate an intense inflammatory response. *Microbes And Infection* 11, 29–39.

Twu O, de Miguel N, Lustig G, Stevens GC, Vashisht AA, Wohlschlegel JA and Johnson PJ (2013) *Trichomonas vaginalis* exosomes deliver cargo to host cells and mediate host:parasite interactions. *PLoS Pathogens* 9. doi: 10.1371/journal.ppat.1003482

Weigelt J (2010) Structural genomics - Impact on biomedicine and drug discovery. *Experimental Cell Research* 316, 1332–1338.

Wekesa AL, Cross KS, O´Donovan O, Dowdall JF, O´Brien O, Doyle M, Byrne L, Phelan JP, Ross MD, Landers R and Harrison M (2014) Predicting carotid artery disease and plaque instability from cell-derived microparticles. *European Journal of vascular and endovascular Surgery* 48, 489–495.

World Health Organization (2002) *Control of Chagas Disease: Second Report of the WHO Expert Committee*. Geneva, WHO Technical Report Series, No. 905.

WHO–World Health Organization (2016). World Malaria Report 2016.

Wowk PF, Zardo ML, Miot HT, Goldenberg S, Carvalho PC and Mörking PA (2017) Proteomic profiling of extracellular vesicles secreted from *Toxoplasma gondii*. *Proteomics* 17, 15–16.

Wyllie MP and Ramirez MI (2017) Microvesicles released during the interaction between *Trypanosoma cruzi* TcI and TcII strains and host blood cells inhibit complement system and increase the infectivity of metacyclic forms of host cells in a strain-independent process. *Pathogens and Disease* 75, 1–10.

Zhang X, Yuan X, Shi H, Wu L, Qian H and Xu W (2015) Exosomes in cancer: small particle, big player. *Journal of Hematology & Oncology* 8, 83.

Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, Zhang B, Wang M, Mao F, Yan Y, Gao S, Gu H, Zhu W and Qian H (2013) Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. *Stem Cell Research & Theraphy* 4, 34.

Zingales B (2017) *Trypanosoma cruzi* genetic diversity: something new for something known about chagas disease manifestations, serodiagnosis and drug sensitivity. *Acta Tropica* xx, xxxx-xxxx, https://doi.org/10.1016/j.

Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G and Amigorena S (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nature Medicine* 4, 594–600.